Health economic evaluation of treatments for Alzheimer′s disease: Impact of new diagnostic criteria

Journal of Internal Medicine

Volumn 275, Issue 3, 2014, Pages 304-316

  Wimo, A ^a,b   Ballard, C ^c   Brayne, C ^d   Gauthier, S ^e   Handels, R ^f   Jones, R W ^g   Jonsson, L ^a,b   Khachaturian, A S ^h   Kramberger, M ⁱ  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g Research Institute for the Care of Older People (RICE)   (United Kingdom)

^h Campaign to Prevent Alzheimer's Disease by 2020 ^*  (Slovenia)

ⁱ UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Alzheimer's disease; Clinical trials; Dementia; Diagnosis; Health economics

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL EXAMINATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; NATIONAL HEALTH ORGANIZATION; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ALZHEIMER'S DISEASE; CLINICAL TRIALS; DEMENTIA; DIAGNOSIS; HEALTH ECONOMICS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEMENTIA; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRODROMAL SYMPTOMS; SOCIOECONOMIC FACTORS;

EID: 84895774085     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12167     Document Type: Article

References (65)

1. Prince M, Bryce R, Albanese E, Wimo A, Wagner R, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75.e2.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-31.
3. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012; 78: 1456-63.
4. Matthews FE, Arthur A, Barnes LE et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382: 1405-12.
5. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9: 1-11 e3.
6. Wimo A, Prince M. World Alzheimer Report 2010. The global economic impact of dementia. London; 2010 Contract No.: Document Number|.
7. ADI. World Alzheimer Report 2011. The benefits of early diagnosis and intervention. London; 2011 Contract No.: Document Number|.
8. Banerjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. Int J Geriatr Psychiatry 2009; 24: 748-54.
9. Corbett A, Stevens J, Aarsland D et al. Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. Int J Geriatr Psychiatry 2012; 27: 628-36.
10. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-27.
11. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
12. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
13. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
14. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9: 1-11.e3.
15. Drummond MF, Sculper MJ, Torrance GW, OBrien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press; 2004.
16. SBU. Dementia. A Systematic Review. Stockholm: Staten beredning för medicinsk utvärdering (SBU) (The Swedish Council on Technology Assessment in Health Care), 2008. Report No.: 172E/1-3 Contract No.: Document Number|.
17. Hort J, O'Brien JT, Gainotti G et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17: 1236-48.
18. Boccardi M, Ganzola R, Bocchetta M et al. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis 2011; 26(Suppl 3): 61-75.
19. Buerger K, Frisoni G, Uspenskaya O et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009; 44: 579-85.
20. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 2009; 6: e1000180.
21. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet 2012; 380: 1441-3.
22. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-9.
23. Wimo A, Religa D, Spångberg K, Edlund A-K, Winblad B, Eriksdotter M. Costs of diagnosing dementia - Results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry 2013; 28: 1039-44.
24. Wimo A, Winblad B, Engedal K et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15: 44-54.
25. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21: 327-40.
26. Feldman H, Gauthier S, Hecker J et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004; 63: 644-50.
27. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
28. Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: state of the art and future directions. Alzheimers Dement 2008; 4: 212-22.
29. Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linköping study. Dement Geriatr Cogn Disord 2000; 11: 223-9.
30. Jagger C, Matthews R, Lindesay J, Robinson T, Croft P, Brayne C. The effect of dementia trends and treatments on longevity and disability: a simulation model based on the MRC cognitive Function and Ageing Study (MRC CFAS). Age Ageing 2009; 38: 319-25; discussion 251.
31. Zhang YL. Potential Cost-effectiveness of a Health Intervention Program with Risk Reductions for Being Demented. Stockholm: Karolinska Intstitutet, 2010.
32. Ahtiluoto S, Ngandu T, Rauramaa R et al. Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (abstract). 10th International Conference of Alzheimer's Disease (ICAD); 2010; Honolulu, USA, 2010.
33. Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B, Saido TC. Gene therapy in Alzheimer's disease - potential for disease modification. J Cell Mol Med 2000; 14: 741-57.
34. Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease-a simulation study. Curr Alzheimer Res 2013; 10: 207-16.
35. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997; 45: 923-8.
36. Aguero-Torres H, Kivipelto M, von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer's disease and what is vascular dementia? A study from the kungsholmen project. Dement Geriatr Cogn Disord 2006; 22: 244-9.
37. Ahtiluoto S, Polvikoski T, Peltonen M et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75: 1195-202.
38. Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers Dement 2012; 9: 58-62.
39. Green C, Shearer J, Ritchie CW, Zajicek JP. Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression. Value Health 2011; 14: 621-30.
40. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs 2012; 72: 789-802.
41. Bond M, Rogers G, Peters J et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012; 16: 1-470.
42. Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer's disease. Drugs Aging 2011; 29: 31-43.
43. Brod M, Stewart AL, Sands L, Walton P. Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL). Gerontologist 1999; 39: 25-35.
44. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med 2002; 64: 510-9.
45. Smith SC, Lamping DL, Banerjee S et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005; 9: 1-93, iii-iv.
46. Weiner MF, Martin-Cook K, Svetlik DA, Saine K, Foster B, Fontaine CS. The quality of life in late-stage dementia (QUALID) scale. J Am Med Dir Assoc 2000; 1: 114-6.
47. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers, 1996.
48. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2000; 9: 121-4.
49. Coucill W, Bryan S, Bentham P, Buckley A, Laight A. EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care 2001; 39: 760-71.
50. Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making 2000; 20: 413-22.
51. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33: 328-36.
52. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 1: 4.
53. Kerner DN, Patterson TL, Grant I, Kaplan RM. Validity of the Quality of Well-Being Scale for patients with Alzheimer's disease. J Aging Health 1998; 10: 44-61.
54. Torrance G. Designing and conducting cost-utility analysis. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers, 1996; 1105-21.
55. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996; 34: 702-22.
56. Tsuchiya A, Dolan P, Shaw R. Measuring people's preferences regarding ageism in health: some methodological issues and some fresh evidence. Soc Sci Med 2003; 57: 687-96.
57. Ekman M, Berg J, Wimo A, Jonsson L, McBurney C. Health utilities in mild cognitive impairment and dementia: a population study in Sweden. Int J Geriatr Psychiatry 2007; 22: 649-55.
58. Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ 1997; 16: 685-702.
59. Seeher K, Low LF, Reppermund S, Brodaty H. Predictors and outcomes for caregivers of people with mild cognitive impairment: a systematic literature review. Alzheimers Dement 2013; 9: 346-55.
60. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22.
61. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1339-41.
62. Jonsson L, Andreasen N, Kilander L et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006; 20: 49-55.
63. Rizzuto D, Bellocco R, Kivipelto M, Clerici F, Wimo A, Fratiglioni L. Dementia after age 75: survival in different severity stages and years of life lost. Curr Alzheimer Res 2012; 9: 795-800.
64. Brayne C, Gao L, Dewey M, Matthews FE. Dementia before death in ageing societies-the promise of prevention and the reality. PLoS Med 2006; 3: e397.
65. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. [pdf] Geneva: WHO, 1968 [updated 1968; cited]; Available from: http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf.